Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Rosuvastatin 20 Mg Oral Tablet Clear all

Conditions: Hypertriglyceridemia
Interventions: rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Advanced Solid Tumors, Metastatic Melanoma
Interventions: losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Healthy Participants
Interventions: Rosuvastatin, ALXN2040; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Drug-Interactions
Interventions: ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sepsis, Acute Lung Injury
Interventions: Rosuvastatin, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 745 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 40
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Healthy, Obese, Overweight
Interventions: Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam, Sodium Bicarbonate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Rosuvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 54
States / cities: Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more

Conditions: Drug Interaction
Interventions: Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Adult Subjects
Interventions: Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and rosuvastatin, Rosuvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 82
States / cities: Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 79 more

Conditions: Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Interventions: AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg), Rosuvastatin 10 mg tablet.; Drug
Lead sponsor: Advenchen Laboratories, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more

Conditions: Healthy Participants
Interventions: AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy
Interventions: TERN-701, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine; Drug
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Millcreek, Utah

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib, Rosuvastatin, Simvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Interventions: Rosuvastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Rheumatoid Arthritis
Interventions: Atorvastatin, Pravastatin, Rosuvastatin, Filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
Interventions: Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 56
States / cities: Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more

Conditions: Dyslipidemia
Interventions: AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Search by objective public record fields.

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

Statins for Acutely Injured Lungs From Sepsis

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)

Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.